CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Grifols SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Grifols SA
Parque Empresarial Can Sant Joan
Avinguda de la Generalitat, 152-158
Phone: +34 935710000p:+34 935710000 SANT CUGAT DEL VALLES, BAR  08174  Spain Ticker: GRFGRF
Business Summary
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes-Yes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2835 In vitro and in vivo diagnostic substances
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
3842 Orthopedic, prosthetic, and surgical appliances and supplies
3841 Surgical and medical instruments and apparatus
8099 Health and allied services, not elsewhere classified
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board, Other External Director Thomas H.Glanzmann 65 9/23/2024 4/5/2006
Chief Executive Officer, Executive Director Jose IgnacioAbia 4/1/2024 2/26/2024
Chief Financial Officer AlfredoArroyo Guerra 1/1/2014
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
GIANT FUNDING CORP.
Biotest AG Landsteinerstr. 5 DREIEICH Germany
Grifols WorldWide Operations Ltd. Embassy House Dublin Ireland
15 additional Subsidiary records available in full report.

Business Names
Business Name
0RDU
Access Biologicals, LLC
Aigües Minerals Vilajuïga, S.A.
91 additional Business Names available in full report.

General Information
Number of Employees: 23,744 (As of 12/31/2023)
Outstanding Shares: 679,629,199 (As of 6/30/2024)
Stock Exchange: MCE
Fax Number: +34 935710267
Email Address: division.international@grifols.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 21, 2024